Select Language
IL-2 R alpha
IL-2 R alpha Overview
| English Name | Interleukin-2 receptor alpha chain | Approved Drugs | 3 |
| Drugs in Clinical Trials | 16 | Target Synonym | TAC antigen，p55，IL2-RA，Interleukin-2 receptor subunit alpha，IL-2-RA，IL-2R subunit alpha，IL2RA，Interleukin 2 Receptor Subunit Alpha，Interleukin 2 Receptor， Alpha，IL-2 Receptor Subunit Alpha，Insulin-Dependent Diabetes Mellitus 10，CD25 Antigen，IDDM10，IMD41，TCGFR，CD25，Interleukin-2 Receptor alpha Subunit，IL-2R alpha |
| Highest Development Stage | Approved | ||
| English Name | Interleukin-2 receptor alpha chain |
| Target Synonym | TAC antigen，p55，IL2-RA，Interleukin-2 receptor subunit alpha，IL-2-RA，IL-2R subunit alpha，IL2RA，Interleukin 2 Receptor Subunit Alpha，Interleukin 2 Receptor， Alpha，IL-2 Receptor Subunit Alpha，Insulin-Dependent Diabetes Mellitus 10，CD25 Antigen，IDDM10，IMD41，TCGFR，CD25，Interleukin-2 Receptor alpha Subunit，IL-2R alpha |
| Approved Drugs | 3 |
| Drugs in Clinical Trials | 16 |
| Highest Development Stage | Approved |
IL-2 R alpha Product List
- Product Category
Protein (11)
- Product Status
Launched (12)
- Species
Human (4)Mouse (2)Canine (1)Cynomolgus (2)Rhesus macaque (1)Rat (1)
- Tag
Fc Tag (1)His Tag (6)His Tag & Avi Tag (3)Fc Tag & Avi Tag (1)
- Conjugate
Unconjugated (7)Biotin-labeled (4)
Add to Cart
Total: 11
- 1
- 2
IL-2 R alpha Background
Interleukin-2 receptor subunit alpha (IL2RA) is also known as IL-2R subunit alpha, IL-2-RA, IL2-RA, TAC antigen, p55, CD antigen CD25, is a type I transmembrane glycoprotein. IL2RA is expressed on activated T cells and regulatory T cells, and is capable of binding IL2 with low affinity by itself. However, a ligand-induced high affinity heterotrimeric receptor complex is produced when IL2RA is associated non-covelently with the IL2 receptor beta and gamma chain, and subsequently initiates the intacellular signal pathways such as MAPK or JAK/STAT. On dendritic cells (DC), CD25 has been previously regarded as an activation marker, while both murine and human DC can express CD25, they do not express the beta-chain of the IL-2 receptor, which is indispensable for the execution of IL-2 signaling.
IL-2 R alpha Synonyms
IL2RA,CD25,p55,IL2-RA,IL-2-RA
Antibody Project Trading Platform
| Project Name | Project Stage | Molecule Type | Molecule Source | Disease Area | Indication |
|---|---|---|---|---|---|
| CD25 mAb - 01 | PCC | Monoclonal | Humanized Mouse | Solid Tumor | Solid tumor |
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Nemvaleukin alfa | RDB-1419; RDB-1450; ALKS-4230 | Phase 3 Clinical | Alkermes Plc | Ovarian Neoplasms; Solid tumours; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Melanoma | Details |
| Basiliximab biobetter (Mabtech/Sorrento) | STI-003 | Phase 3 Clinical | Taizhou Maibo Taike Biotechnology Co Ltd | Autoimmune Diseases | Details |
| PT-101 | PT-101; MK-6194; PT101 | Phase 2 Clinical | Pandion Therapeutics | Lupus Erythematosus, Systemic; Colitis, Ulcerative; Vitiligo; Dermatitis, Atopic | Details |
| LMB-2 | LMB-2; LMB-2a | Phase 2 Clinical | National Cancer Institute | Leukemia; Skin Melanoma; Leukemia, Hairy Cell; Myeloproliferative Disorders; Myelodysplastic Syndromes; Skin Neoplasms; Lymphoma; Myelodysplastic-Myeloproliferative Diseases; Leukemia, T-Cell | Details |
| Camidanlumab tesirine | ADCT-301 | Phase 2 Clinical | Adc Therapeutics Sa, Genmab A/S | Myelodysplastic Syndromes; Carcinoma, Non-Small-Cell Lung; Melanoma; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Fallopian Tube Neoplasms; Colorectal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Urinary Bladder Neoplasms; Ovarian Neoplasms; Myeloproliferative Disorders; Pancreatic Neoplasms; Hodgkin Disease; Triple Negative Breast Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck | Details |
| Humanized Anti-CD25 Antibody(Institute of Hematology & Blood Diseases Hospital) | Phase 2 Clinical | Institute Of Hematology & Blood Diseases Hospital | Graft vs Host Disease | Details | |
| 90Y Basiliximab | Phase 2 Clinical | City Of Hope National Medical Center | Hodgkin Disease; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous | Details | |
| Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 | HuMikβ1-1 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd, National Institutes Of Health | Leukemia; Leukemia, Lymphoid; Celiac Disease; Paraparesis, Tropical Spastic; Leukemia, Large Granular Lymphocytic | Details |
| Vopikitug | RO-7296682; RG-6292 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours | Details |
| BA-1106 | TS-1904; BA-1106; RR-102 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Solid tumours | Details |
| XmAb-564 | XmAb-564; XmAb564; XmAb-27564 | Phase 1 Clinical | Xencor Inc | Autoimmune Diseases; Psoriasis; Dermatitis, Atopic | Details |
| PF-08046032 | PF-08046032 | Phase 1 Clinical | Pfizer Inc | Lymphoma, T-Cell, Peripheral; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| IL2 CD25 fusion protein (Bristol-Myers Squibb) | Phase 1 Clinical | University Of Miami | Autoimmune Diseases | Details | |
| 9MW-3911 | 9MW3911; 9MW-3911 | Phase 1 Clinical | Nanjing Nuo Aixin Biotechnology Co Ltd | Neoplasms | Details |
| In 111-DOTA-Basiliximab | Phase 1 Clinical | City Of Hope National Medical Center | Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details | |
| BMS-986326 | BMS-986326 | Phase 1 Clinical | Bristol-Myers Squibb Company | Lupus Vulgaris; Dermatitis, Atopic | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Daclizumab biosimilar (Shanghai CP Guojian) | Approved | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | 健尼哌 | Mainland China | Rejection of renal transplantation | null | 2011-01-12 | Rejection of renal transplantation | Details | |
| Daclizumab | R-35; BIIB-019; RO-247375 | Approved | Abbvie Inc, Biogen Inc, F. Hoffmann-La Roche Ltd | Zinbryta, Zenapax | United States | Rejection of organ transplantation | F. Hoffmann-La Roche Ag | 1997-12-10 | Rejection of organ transplantation; Behcet Syndrome; Melanoma; Leukemia, T-Cell; Lymphoma; Rejection in heart transplantation; Thrombocytopenia; Uveitis; Iritis; Asthma; Colitis, Ulcerative; Uveitis, Anterior; Anemia, Aplastic; Breast Neoplasms; Psoriasis; Retinal Diseases; Multiple Sclerosis, Relapsing-Remitting; Carcinoma, Ductal; Radiation Injuries; Arthritis, Juvenile; Multiple Sclerosis; Red-Cell Aplasia, Pure; Anemia, Diamond-Blackfan; Myelodysplastic Syndromes; HTLV-I Infections; Inflammatory Bowel Diseases; Gastrointestinal Diseases; Leukemia; Diabetes Mellitus, Type 1; Granulomatosis with Polyangiitis; HIV Infections | Details |
| Basiliximab | CHT-25; chRFT5; CHI-621; SDZ-CHI-621 | Approved | Novartis Pharma Ag | 舒莱, Simulect | United States | Rejection of organ transplantation | Novartis Pharma Ag | 1998-05-12 | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Kidney Failure, Chronic; Leukemia, Myeloid, Acute; Uveitis; Lymphoma, Non-Hodgkin; Emphysema; Pulmonary Disease, Chronic Obstructive; Primary Myelofibrosis; Colitis, Ulcerative; Anemia, Aplastic; Rejection of renal transplantation; Multiple Myeloma; Rejection of organ transplantation; Coronavirus Disease 2019 (COVID-19); Myelodysplastic Syndromes; Hodgkin Disease; Hemoglobinuria, Paroxysmal; Keratoplasty rejection; Cytokine Release Syndrome; Leukemia, Myelogenous, Chronic | Details |
Product Reviews
T***I2025-11-07
0People LikeWe purchased this protein mainly for ELISA and SPR experiments. This protein exhibits extremely high activity. Its affinity differences with different IgG subtypes are clearly distinguishable, the signal-to-noise ratio is extremely high, effectively avoiding false negative or false positive results.- E***n2023-04-08 0People LikeYeast cells expressing and displaying different IL2 variants were incubated 1h in the presence of CD25 protein with His tag (Human Il-2 R alpha Acrobiosystems #ILA-H52H9) at a final concentration of 4µg/ml. Next, cells were washed and incubated with a mouse Anti-His-PE. The yeast cells were washed and were analyzed using FACS. We observed detectable amounts of fluorescence bound to yeast cells displaying specific IL2 variants confirming that CD25 could bind to certain constructs and providing evidence that certain IL2 variants were correctly folded.
- 1***22022-08-03 0People LikeI purchased the company’s mouse-derived CD25 protein for the evaluation of CD25 antibody affinity. It achieved a high sensitivity detection with a small amount! Very satisfied, will come back to purchase more if needed!
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email：order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland